Srinivas Bontha
Endocrinology, Diabetes & Metabolism · Marietta, GANPI 1770676405
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,468 and has fallen 90.7% since, to $324 in 2023.
Across 341 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$522
- Amgen$498
- Lilly USA, LLC$484
- Novo Nordisk$420
- Abbott$280
- Mannkind Corporation$230
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,515100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 26 | $522 |
| Amgen | 27 | $498 |
| Lilly USA, LLC | 35 | $484 |
| Novo Nordisk | 31 | $420 |
| Abbott | 14 | $280 |
| Mannkind Corporation | 14 | $230 |
| Insulet Corporation | 14 | $222 |
| Xeris Pharmaceuticals, Inc. | 10 | $204 |
| Boehringer Ingelheim | 12 | $201 |
| AbbVie | 14 | $195 |
| Radius Health, Inc. | 8 | $191 |
| Merck | 14 | $176 |
| Tandem Diabetes Care, Inc. | 11 | $171 |
| Antares Pharma, Inc. | 10 | $163 |
| Amneal Pharmaceuticals LLC | 9 | $156 |
| AstraZeneca | 10 | $152 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $134 |
| Corcept Therapeutics | 7 | $110 |
| Dexcom, Inc. | 5 | $101 |
| Shire North American Group Inc | 6 | $100 |
| IBSA Pharma Inc. | 6 | $97 |
| Bayer | 5 | $96 |
| Amarin Pharma, Inc. | 6 | $82 |
| Nalpropion Pharmaceuticals LLC | 5 | $73 |
| Johnson & Johnson | 5 | $62 |
| Ultragenyx Pharmaceutical Inc. | 2 | $49 |
| Kyowa Kirin, Inc. | 1 | $47 |
| Amryt Pharma Holdings Ltd | 2 | $40 |
| Pfizer | 3 | $38 |
| Valeritas, Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| Companion Medical, Inc. | 2 | $32 |
| Endo Pharmaceuticals Inc. | 2 | $31 |
| Zealand Pharma US, Inc. | 1 | $26 |
| Acerus Pharmaceuticals Corporation | 1 | $17 |
| Medtronic | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Cequr Corporation | 1 | $14 |
| Vivus LLC | 1 | $11 |
How this compares
$5,530 in reported general payments places this provider in the 65th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,314 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Marietta
- Miguel MunozMarietta$476K
- Jean MolinaryMarietta$8K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.